$2 here well this might be my "dud" of the year so far. Still have the faith based on what I know but hope we see more Form 4's in the near future here!
In connection with the Asset Purchase agreement, SCYNEXIS is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. SCYNEXIS retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized.